$18.500
0.000 (0.00%)收盘时
SLP 资讯
SLP 事件
Simulations Plus Partners with Global Pharma to Develop AI Drug Models
Simulations Plus announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology, within an active therapeutic development program. The collaboration will evaluate how AI-enabled exploration of mechanistic model structures can substantially reduce the time required to build and evaluate QSP models. Under this collaboration, the pharmaceutical partner will use Turin within a hosted environment, supported by Simulations Plus scientists, who will provide scientific guidance throughout model evaluation.
Simulations Plus Completes Acquisition by Altaris, Shareholders Receive $18.50 per Share
Simulations Plus announced the completion of its acquisition by affiliates of Altaris. The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations Plus shareholder received $18.50 in cash per share. As a result of the completion of the transaction, Simulations Plus has become a privately held company, and its common stock will no longer trade on the Nasdaq Global Select Market.
Simulations Plus Receives FDA License for ADMET Predictor
Simulations Plus announced that the FDA's Cosmetics Regulatory Science Branch has licensed ADMET Predictor to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology within the FDA. The ADMET Predictor platform provides researchers with advanced artificial intelligence and machine learning technology, descriptors, data, and predictive models to predict endpoint properties and systemic exposure in animals and humans.
Simulations Plus Reports Q3 Revenue of $21.9M
Reports Q3 revenue $21.9M vs. $20.4M last year. "We delivered solid third quarter results, with revenue increasing 7%, highlighted by strength in our services revenue, which grew 20%, while software revenue was flat year over year," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "Our performance reflects the resilience of our business model and the value our solutions provide to clients across the drug development lifecycle."
Nvidia Launches BioNeMo Toolkit to Advance AI Research
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.TECH SELLOFF:Micronand Nvidiaare leading a broad tech selloff on Tuesday, as investors weigh concerns around AI spending levels and a more hawkish interest-rate backdrop. Traders appear increasingly focused on whether enormous capital spending commitments across AI infrastructure, data centers and chips can justify current valuations.NVIDIA/BIONEMO:Nvidia announced Nvidia BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era. Including more than a decade's worth of Nvidia life sciences libraries, tools and open models, the toolkit enables AI agents, scientists and labs to work together by gathering evidence, reasoning across findings, running computational experiments and recommending the next best steps to accelerate discovery. "Frontier models are the brains. BioNeMo is the scientific toolbox. Together, they give AI agents the skills of a PhD research assistant and the speed of a supercomputer," said Jensen Huang, founder and CEO of Nvidia. "For the first time, researchers can build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows. This is a new way to do science - one that can dramatically accelerate discovery across biology, chemistry, genomics and medicine."NVIDIA/SIMULATIONSPLUS:Simulations Plusannounced it is building the agentic layer of Composer using the Nvidia BioNeMo Agent Toolkit. The initiative expands the companies' collaboration announced in May 2026, extending their work in GPU-accelerated simulation and AI-assisted modeling workflows into agentic drug development. Together, the companies are combining AI reasoning, scientific literature, validated computational engines, and scalable compute within a scientific workflow, they said.NVIDIA/PENGUIN:Penguin Solutionshas become an Nvidia AI Factory Specialized Partner, joining a select group of Nvidia Partner Network solution providers. Penguin achieved this invitation-only Nvidia AI Factory specialization by completing Nvidia's comprehensive training, maintaining the relevant competencies, meeting solution requirements, and bringing proven experience in designing, building, deploying, and operating full-stack, Nvidia-based AI factory infrastructure for enterprise and hyperscale customers.QUALCOMM/MODULAR:Qualcommis in advanced discussions to acquire Modular in a deal valuing the AI chip startup at roughly $4B, Bloomberg's Liana Baker and Ryan Gould report, citing people familiar with the matter. A transaction could be formally announced in the coming weeks, though a final agreement hasn't been reached yet, the authors note.IBM/OPENAI:IBMannounced it has joined the OpenAI Daybreak Cyber Partner Program, bringing frontier AI capabilities into security operations. Building on the recently announced Project Lightwell, as part of this effort IBM has launched a new application security service that uses the cyber capabilities of OpenAI's models to help organizations identify and validate software vulnerabilities. Through this program, IBM is working with OpenAI to apply advanced AI capabilities to be deployed defensively inside enterprise workflows.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。